New Data Illustrates Variances In The Use Of Evidence-Based Heart Failure Treatments

Last but not least...patient education...BD

According to the baseline results, the use of ACE inhibitors/ARBs (angiotensin II receptor blockers) and beta-blockers were relatively high in patients eligible for these therapies (80 percent and 86 percent of eligible patients, respectively). However, fewer patients received other life-saving treatments and devices for which they were eligible based on current medical guidelines. These included:

- Aldosterone antagonists (36 percent of eligible patients)
- Anticoagulation for atrial fibrillation (69 percent of eligible patients)
- Cardiac resynchronization therapy (CRT), including both CRT-defibrillators (CRT-D) and CRT-pacemaker devices (39 percent of eligible patients)
- Implantable cardioverter defibrillator (ICD) therapy, including both ICD-only and CRT-D devices (51 percent of eligible patients)
- HF education (61 percent of eligible patients)